Sujal Shah

This profile gathers the share dealings of Sujal Shah in CymaBay Therapeutics, Inc., where the filings describe the role as chief executive. The record holds 39 filings, for trades running from 16 September 2014 to 22 March 2024.

In open-market terms, that means 17 purchases worth €547k on one side and 5 sales worth €3.0M on the other. The net balance comes to €2.5M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 1 share grant and 14 option exercises.

A typical purchase (the median) is worth €30k. 5 out of 15 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 22 March 2024, the filings show a transaction in CymaBay Therapeutics, Inc. The clock since the last published purchase (7 June 2022) now reads 1,602 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.